Kinetics of serum CXCL9 levels during PEG-IFN treatment in CHB patients with or without SVR.

<p>In patients with SVR, CXCL9 levels significantly decreased from baseline to week 12, whereas in patients without SVR, CXCL9 levels remained high at week 12 but decreased later from week 12 to EOT. Data were presented as mean ± standard errors of the means (SEM). EOT: end of treatment.